Development of a Minimally Invasive Seizure Gauge

Sponsor
Seer Medical Pty Ltd (Industry)
Overall Status
Enrolling by invitation
CT.gov ID
NCT03882671
Collaborator
(none)
40
1
1
35
1.1

Study Details

Study Description

Brief Summary

The researchers are trying to assess changes in physiological signals before and during seizures.

Condition or Disease Intervention/Treatment Phase
  • Device: EpiTel Epilog
  • Device: Empatica E4
  • Device: GENEActiv
N/A

Detailed Description

Subjects that are undergoing video EEG monitoring in their home for their epilepsy at Seer Medical will be consented to participate in this study for a minimum of two days and/or the duration of their monitoring period for their clinical care. Subjects will be asked to wear up to 4 different commercially available seizure detection devices and complete surveys.

When the subjects clinical EEG monitoring is completed data scientists will analyze the data to identify patterns.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Development of a Minimally Invasive Seizure Gauge
Actual Study Start Date :
Jan 1, 2019
Anticipated Primary Completion Date :
Nov 1, 2021
Anticipated Study Completion Date :
Dec 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Monitoring Device

Subjects will be asked to wear up to 3 different noninvasive seizure detection devices including EpiTel EpiLog, Empatica E4, GeneActiv

Device: EpiTel Epilog
EEG recording device

Device: Empatica E4
PPG, sweat level, temperature and accelerometry recording device

Device: GENEActiv
Temperature, light level and accelerometry recording device

Outcome Measures

Primary Outcome Measures

  1. Multimodal Assessment of Physiological Signals During Seizure Events Measurable with Wearable Sensors [2-7 days approximately]

    We will collect physiological signals with the three wearable, noninvasive biosensors in Seer Medical patients undergoing scalp-recorded video EEG-ECG as part of their clinical epilepsy evaluation. These signals include temperature, light level, EEG, heart rate, galvanic skin response, PPG, accelerometry. We will evaluate biosignals based on reliability to detect seizures.

  2. Wearable Sensors Comfort Assessment [2-7 days approximately]

    We will collect physiological signals with the three wearable, noninvasive biosensors in Seer Medical patients. We will evaluate subject comfort and ease of use for each device, measured through quantitative surveys.

  3. Seizure Detection and Prediction using Multimodal Physiological Data [2-7 days approximately]

    We will apply data mining and machine learning methods to identify patterns in the collected physiological signals and correlate these patterns with the timing of seizures identified by the patient's clinical video-EEG monitoring. We will use sensitivity and specificity measures to determine which signals are most useful in detecting and predicting seizure events.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with epilepsy undergoing scalp EEG for clinical care, or an implanted device capable of monitoring brain activity and identifying seizures

  • Patients of age 18 or above

Exclusion Criteria:
  • Cognitive or psychiatric condition rendering patient unable to cooperate with data collection, or manage and recharge smart watch and tablet computer devices.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Seer Medical Melbourne Victoria Australia 3000

Sponsors and Collaborators

  • Seer Medical Pty Ltd

Investigators

  • Principal Investigator: Dean R Freestone, PhD BEng, CEO

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Seer Medical Pty Ltd
ClinicalTrials.gov Identifier:
NCT03882671
Other Study ID Numbers:
  • HREC042_18
First Posted:
Mar 20, 2019
Last Update Posted:
Sep 22, 2021
Last Verified:
Sep 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 22, 2021